Vipivotide tetraxetan
| CAS No. | 1702967-37-0 | Cat. No. | BCP35795 |
| Name | Vipivotide tetraxetan | ||
| Synonyms | PSMA-617; PSMA617; PSMA 617; | ||
| Formula | C49H71N9O16 | M. Wt | 1042.15 |
| Description | Vipivotide tetraxetan is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC. | ||
| Pathways | Others Pathway | ||
| Targets | ADC Related | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.